Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of “Buy” by Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been assigned a consensus rating of “Buy” from the twelve research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $43.3750.

A number of equities analysts have commented on the stock. BTIG Research boosted their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. JPMorgan Chase & Co. increased their target price on Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research note on Monday, September 29th. Wells Fargo & Company started coverage on Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price target on the stock. Finally, Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th.

Maze Therapeutics Stock Down 3.7%

NASDAQ:MAZE opened at $40.55 on Tuesday. The stock has a market cap of $1.95 billion and a P/E ratio of -1.94. The business’s 50-day moving average price is $36.13 and its two-hundred day moving average price is $24.27. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $43.29.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Institutional Trading of Maze Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC bought a new position in Maze Therapeutics during the second quarter valued at approximately $28,000. Ameritas Investment Partners Inc. boosted its stake in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares in the last quarter. Corebridge Financial Inc. purchased a new stake in shares of Maze Therapeutics in the 1st quarter valued at $48,000. Russell Investments Group Ltd. grew its holdings in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Maze Therapeutics in the 3rd quarter worth $52,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.